Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100165 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00100165 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 29 participants.
The verdict
NCT00100165, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.
Interventions
- DRUG Placebo
- DRUG 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg
- DRUG 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100165
The ClinicalTrials.gov registry entry for NCT00100165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00100165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100165 about?
NCT00100165 is a clinical study titled "Phase 2 Trial of a Nicotinic Agonist in Schizophrenia". The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.
What is the current status of trial NCT00100165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-01. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00100165?
The interventions under investigation include: Placebo (DRUG), 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg (DRUG), 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg (DRUG).
Who is sponsoring clinical trial NCT00100165?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.